172 related articles for article (PubMed ID: 29872726)
1. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma.
Thibodeau ML; Bonakdar M; Zhao E; Mungall KL; Reisle C; Zhang W; Bye MH; Thiessen N; Bleile D; Mungall AJ; Ma YP; Jones MR; Renouf DJ; Lim HJ; Yip S; Ng T; Ho C; Laskin J; Marra MA; Schrader KA; Jones SJM
NPJ Precis Oncol; 2018; 2(1):8. PubMed ID: 29872726
[TBL] [Abstract][Full Text] [Related]
2. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.
Bosic M; Kirchner M; Brasanac D; Leichsenring J; Lier A; Volckmar AL; Oliveira C; Buchhalter I; Stögbauer F; Zivkovic-Perisic S; Goeppert B; Schirmacher P; Penzel R; Endris V; Stenzinger A
Pathology; 2018 Apr; 50(3):327-332. PubMed ID: 29269125
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Denisova E; Westphal D; Surowy HM; Meier F; Hutter B; Reifenberger J; Rütten A; Schulz A; Sergon M; Ziemer M; Brors B; Betz RC; Redler S
Cancer Gene Ther; 2022 Jun; 29(6):697-708. PubMed ID: 34045664
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
5. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
[TBL] [Abstract][Full Text] [Related]
6. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of p16 and RB protein in eccrine porocarcinoma.
Gu LH; Ichiki Y; Kitajima Y
J Cutan Pathol; 2002 Sep; 29(8):473-9. PubMed ID: 12207741
[TBL] [Abstract][Full Text] [Related]
8. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
9. Genetic and methylation status of CDKN2A (p14
Chantre-Justino M; Gonçalves da Veiga Pires I; Cardoso Figueiredo M; Dos Santos Moreira A; Alves G; Faria Ornellas MH
Hum Pathol; 2022 Jan; 119():94-104. PubMed ID: 34826422
[TBL] [Abstract][Full Text] [Related]
10. Germline hemizygous deletion of
Chan SH; Lim WK; Michalski ST; Lim JQ; Ishak NDB; Met-Domestici M; Young CNC; Vikstrom K; Esplin ED; Fulbright J; Ang MK; Wee J; Sittampalam K; Farid M; Lincoln SE; Itahana K; Abdullah S; Teh BT; Ngeow J
NPJ Genom Med; 2016; 1():16015. PubMed ID: 29263814
[TBL] [Abstract][Full Text] [Related]
11. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Westphal D; Garzarolli M; Sergon M; Horak P; Hutter B; Becker JC; Wiegel M; Maczey E; Blum S; Grosche-Schlee S; Rütten A; Ugurel S; Stenzinger A; Glimm H; Aust D; Baretton G; Beissert S; Fröhling S; Redler S; Surowy H; Meier F
Br J Dermatol; 2021 Dec; 185(6):1186-1199. PubMed ID: 34185311
[TBL] [Abstract][Full Text] [Related]
12. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
13. Altered Rb, p16, and p53 expression is specific for porocarcinoma relative to poroma.
Zahn J; Chan MP; Wang G; Patel RM; Andea AA; Bresler SC; Harms PW
J Cutan Pathol; 2019 Sep; 46(9):659-664. PubMed ID: 31012122
[TBL] [Abstract][Full Text] [Related]
14. P53 protein expression in eccrine poroma and porocarcinoma.
Akalin T; Sen S; Yücetürk A; Kandiloğlu G
Am J Dermatopathol; 2001 Oct; 23(5):402-6. PubMed ID: 11801771
[TBL] [Abstract][Full Text] [Related]
15. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z; Lim SY; Rizos H
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
[TBL] [Abstract][Full Text] [Related]
16. Detection of somatic copy number deletion of the
Tian Y; Zhou J; Qiao J; Liu Z; Gu L; Zhang B; Lu Y; Xing R; Deng D
Front Oncol; 2022; 12():1038380. PubMed ID: 36531022
[TBL] [Abstract][Full Text] [Related]
17. [Eccrine porocarcinoma of the scalp].
Ekmekcı S; Lebe B
Turk Patoloji Derg; 2013; 29(2):156-9. PubMed ID: 23661356
[TBL] [Abstract][Full Text] [Related]
18. High Positive Correlations between
Drak Alsibai K; Vacher S; Meseure D; Nicolas A; Lae M; Schnitzler A; Chemlali W; Cros J; Longchampt E; Cacheux W; Pignot G; Callens C; Pasmant E; Allory Y; Bieche I
Noncoding RNA; 2019 Aug; 5(3):. PubMed ID: 31438464
[TBL] [Abstract][Full Text] [Related]
19. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.
Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB
Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439
[TBL] [Abstract][Full Text] [Related]
20. Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.
Lavoie JM; Csizmok V; Williamson LM; Culibrk L; Wang G; Marra MA; Laskin J; Jones SJM; Renouf DJ; Kollmannsberger CK
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
